The partnership promotes an innovative, proven alternative to invasive assessment of coronary physiology EDEN PRAIRIE, Minn., Dec. 15, 2020 /PRNewswire/ — ACIST Medical Systems, Inc., a Bracco Group Company, today announced a formal distribution partnership with Medis Medical Imaging to co-market in North America. This partnership is focused on Quantitative Flow Ratio (QFR®), a […]
Other News
iRhythm Technologies President and CEO Kevin King to Retire; Michael Coyle Joins Company as President and CEO Effective January 12, 2021
SAN FRANCISCO, Dec. 14, 2020 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that Kevin King will retire as President and CEO effective January 12, 2021. Mr. King will continue to serve on iRhythm’s board of directors and […]
Baylis Medical Launches 2-French Electrophysiology Catheter in Canada for Deeper Coronary Sinus Mapping
TORONTO, Dec. 15, 2020 /CNW/ – Baylis Medical announced today the Canadian launch of its EPstar Electrophysiology Catheters. The launch enables physicians to reach previously inaccessible areas of the heart for procedure mapping, by making available the smallest diagnostic catheter in the Canadian electrophysiology market. The EPstar catheter family includes a 2F catheter and a […]
Foldax Receives FDA Approval to Initiate Clinical Study of Biopolymer Mitral Heart Valve
SALT LAKE CITY–(BUSINESS WIRE)–Foldax®, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted IDE approval for the company to initiate a U.S. clinical study of its Tria™ biopolymer mitral surgical heart valve. The company anticipates the first use of its mitral valve in a human will […]
BioCardia Anticipates DSMB Feedback on Interim Data From Pivotal Phase 3 CardiAMP Heart Failure Trial
SAN CARLOS, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announces that it anticipates data safety monitoring board (DSMB) verbal feedback by the end of December 15, 2020 on interim data from the Company’s pivotal Phase 3 CardiAMP Heart Failure Trial that is currently enrolling […]
New JAMA Network Open Publication Demonstrates the Coronary CT- HeartFlow Analysis Pathway Is ‘Dominant’ Compared to Stress Testing in Cost-Effectiveness Analysis
REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc., a leader in revolutionizing precision heartcare, announced that a new cost-effectiveness analysis found a diagnostic pathway which utilizes coronary computed tomography angiography (CTA) with the HeartFlow FFRct Analysis to be “dominant” (less costly and more effective) as compared to stress testing for assessing patients with […]
Acceleron Receives Orphan Designation from the European Commission (EC) for Sotatercept in Pulmonary Arterial Hypertension (PAH)
– Sotatercept received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) in PAH in 2019 – – In the spring of 2020, sotatercept received Breakthrough Therapy designation from the FDA and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), both in PAH – December 14, […]
Caladrius Biosciences Provides Year-End 2020 Strategic Portfolio Update
Program strategy and prioritization supports projection of available capital through 2021 BASKING RIDGE, N.J., Dec. 14, 2020 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company has […]
Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results
REDUCE-IT® EPA Encore Presentation reinforces Eicosapentaenoic Acid (EPA) levels from VASCEPA® (icosapent ethyl) strongly correlated to cardiovascular outcomes, more so than other biomarkers VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in outpatient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reactive protein (hsCRP) with […]
Efemoral Medical Announces Successful First-In-Human Use of The Efemoral™ Vascular Scaffold System
New bioresorbable treatment option aims to improve outcomes for patients suffering from peripheral arterial disease LOS ALTOS, Calif., Dec. 14, 2020 /PRNewswire/ — Efemoral Medical, developer of advanced interventional bioresorbable therapies, today announced the first-in-human (FIH) use of the company’s Efemoral™ Vascular Scaffold System (EVSS) with FlexStep™ Technology in the EFEMORAL I FIH clinical study. […]



